Easywell Biomedicals Overview
Latest ROE for Easywell Biomedicals: -2.29% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-2.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 1799.TWO is -2.29%. That is below the sector sector average of 11.75%. Investors often review this figure alongside Easywell Biomedicals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 1799.TWO currently prints -2.29% for ROE, while the sector average sits near 11.75%. That is roughly 119.5% below the sector mean. Large gaps often invite a closer look at Easywell Biomedicals's growth, margins, and balance sheet.
Return on Equity shows how effectively Easywell Biomedicals converts resources into returns. At -2.29%, 1799.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 1799.TWO's ROE (-2.29%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
